You are here

Metformin Improves BMI and Blood Glucose Levels in Obese Children

First evidence that front-line diabetes drug delays onset of type 2 diabetes in children (Dec. 10)

Metformin therapy has a beneficial treatment effect over placebo in improving the body mass index (BMI) and fasting glucose levels in obese children, according to a new study accepted for publication in the Journal of Clinical Endocrinology & Metabolism. The study showed that the reduction in BMI was sustained for 6 months.

Childhood obesity has increased globally over the last two decades, and it is linked to an increase in the diagnosis of type 2 diabetes in childhood — previously a condition that was diagnosed only in adults.

Metformin is a first-line drug for type 2 diabetes that has been used for decades. In adults, metformin delays the onset of type 2 diabetes, but there is no evidence that the drug has a similar effect in children.

“Our findings provide evidence that a treatment course of metformin is clinically useful, safe, and well-tolerated in obese children who are at risk for type 2 diabetes,” said lead author Deborah Kendall, MD. "Metformin may also provide a stimulus for lifestyle changes and may potentially reduce long-term risk for type 2 diabetes and its associated health problems.”

The prospective, randomized, double-blind, placebo-controlled trial was conducted at pediatric endocrine centers in the U.K. and involved 151 obese children and young people with hyperinsulinemia and/or impaired fasting glucose or impaired glucose tolerance. The study participants received either metformin or placebo daily for 6 months.

“Our results show that metformin can improve BMI and blood glucose levels in obese children, but longer-term effects, such as a reduction in the incidence of type 2 diabetes, need further study,” Kendall noted.

Source: The Endocrine Society; December 10, 2012.

Recent Headlines

NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens
Primary Immunodeficiencies Affect 250,000 People in U.S.
More Than 25% of Patients Responded to Xpovio/Dexamethasone Combo
Attacks Cancerous Cells, Leaves Healthy Tissues Alone
Moderates Pre-diabetes Progression, Reduces Cholesterol Levels